Isotretinoin Prostate Cancer Trial

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 6
Volume 11
Issue 6

NEW YORK-The final report of a phase II study suggests that the early addition of 13-cis-retinoic acid (isotretinoin, Acutane) to hormone therapy may enhance PSA responses in advanced androgen-dependent prostate cancer. Anna C. Ferrari, MD, of Mt. Sinai School of Medicine, New York, presented the results at the Chemotherapy Foundation Symposium XIX (abstract 58).

NEW YORK—The final report of a phase II study suggests that the early addition of 13-cis-retinoic acid (isotretinoin, Acutane) to hormone therapy may enhance PSA responses in advanced androgen-dependent prostate cancer. Anna C. Ferrari, MD, of Mt. Sinai School of Medicine, New York, presented the results at the Chemotherapy Foundation Symposium XIX (abstract 58).

A total of 34 hormone-naive patients with stage D1/D2 prostate cancer were given hormone therapy for 1 year. Patients randomized to arm 1 also received isotretinoin for the first 12 weeks. From weeks 14 to 25, isotretinoin was added to the regimen of arm 2.

After 12 weeks, the median PSA in the early isotretinoin arm had dropped to 0.5 ng/mL and that in the second cohort to 0.7 ng/mL, a difference that was not significant. By week 25, the median nadirs were 0.1 and 0.4 ng/mL, respectively. It remained at 0.1 ng/mL at 36 weeks and 1 year in the early isotretinoin group vs 0.4 ng/mL at 36 weeks and 0.3 ng/mL at the end of the year in the other group.

Complete biochemical responses were achieved by 7 of the 15 patients who received isotretinoin early vs 3 of the 15 given it after crossover. The study was not powered "to determine if this effect was truly due to potentiation of hormone therapy," Dr. Ferrari noted. At all time points, the early isotretinoin patients achieved an undetectable PSA level sooner than controls. By 1 year, more than double the number of patients in arm 1 had achieved an undetectable PSA, and it was sustained for a longer period of time. 

Related Videos
Ongoing research may clarify the potential benefit of avelumab when administered in combination with other agents in advanced urothelial carcinoma.
Spatial analyses may help determine factors that influence responses to sacituzumab govitecan-containing regimens in urothelial carcinoma.
Attending educational sessions may help with understanding how to manage toxicities associated with enfortumab vedotin in rare genitourinary cancers.
Two women in genitourinary oncology discuss their experiences with figuring out when to begin a family and how to prioritize both work and children.
Over the past few decades, the prostate cancer space has evolved with increased funding for clinical trial creation and enrollment.
Related Content